Stock

Decoy Therapeutics

DCOY

Biotechnology · Healthcare

Price

$4.23

+1.13 (+36.45%)

Market Cap

$2.3M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — nothing to grade.

This is a pre-revenue company — it has no sales yet, just exploration or development costs. There’s no operating business to grade on profitability, margins or cash flow, so the Winston Score stays blank until it starts booking revenue.

Track this stock — start free trial

Share count rising — dilution

+3392.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 14K (2021) → 482K (2025)

§Winston Score History

The full picture

Decoy Therapeutics is a small biotechnology company focused on developing new medicines to treat diseases. The company works on early-stage drug candidates, meaning its treatments are still being researched and tested rather than sold to patients. It operates in the biotech industry, where companies spend years and large amounts of money trying to bring new therapies to market.

As a pre-revenue biotech, Decoy Therapeutics does not yet generate meaningful sales. It funds its operations primarily through equity financing and capital raises. The company is very small by market capitalization and faces the significant risks common to early-stage biotechs, including the possibility that its drug candidates may never receive regulatory approval. Its path forward depends on achieving positive clinical or preclinical results that could attract partnerships or additional funding.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+34.1% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$368,170/ year

↓ Declining (-52% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.6%ownership

Relatively low insider ownership

Cash Runway

~9 months

$8M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Decoy Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-343.5%

Weak — -343.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.81

Elevated debt (1.81)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial